Oncomed to Exploit Fluidigm’s Microfluidic Devices in Cancer Stem Cell Research
OncoMed Pharmaceuticals is tapping Fluidigm’s microfluidic tools for the analysis of tumor-cell heterogeneity, including cancer stem cells. The aim is to identify unique drug targets as well as to evaluate and develop treatments against them. OncoMed will initially use Fluidigm’s BioMark
[Read the full article here]Related News:
Bayer, OncoMed expand cancer stem cell deal
Stanford University Uses Fluidigm Integrated Fluidic Circuits To Help Identify The Source Of Cancer Stem Cell's … (Medical News Today)
OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics